Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06095583
Title Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Shanghai Junshi Bioscience Co., Ltd.
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | FRA | ESP | DEU | BEL

No variant requirements are available.